[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mucus-plug\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mucus-plug":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100627014","simeox-200-us-study-100627014",false,"NCT07443124","Simeox 200 US Study","A Pilot Study to Assess the Effects of Simeox 200 Airway Clearance Device in Bronchiectasis Patients With Chronic Mucus Hypersecretion","IMPACT","Inclusion Criteria:\n\n1. Diagnosis of bronchiectasis confirmed by computed chest tomography (CT chest) performed within the prior 36 months\n2. Persistent productive cough for which daily airway clearance therapy is prescribed.\n3. Daily sputum production estimated at \\> 1 tsp or 5 ml\n4. Clinically stable on medical regimen with no pulmonary exacerbation in the past 4 weeks prior to study enrolment\n5. Subject able to sign informed consent\n\nExclusion Criteria:\n\n1. Inability to cough forcefully and independently, as determined by the clinician\n2. Ventilatory assistance with endotracheal tube, tracheostomy tube, or mask (not including nocturnal CPAP)\n3. Neuromuscular disease with muscle respiratory weakness\n4. Severe restrictive lung disease defined as Forced Vital Capacity (FVC) \\\u003C60% of predicted\n5. Unstable cardiac disease (e.g. major cardiac arrhythmia, unstable heart failure, heart attack, unstable angina)\n6. Hemodynamic instability, as determined by the clinician\n7. Airway at risk for aspiration, as determined by the clinician\n8. Uncontrolled gastroesophageal reflux disease (GERD) as determined by the clinician\n9. Upper airway surgery in the prior 3 months\n10. Cardiothoracic surgery, including esophageal surgery, in the prior 6 months\n11. Anticipated hospitalization within the next 2 weeks\n12. History of pneumothorax within the prior 6 months\n13. History of haemoptysis treated with embolization within the prior 12 months\n14. Inability to use airway clearance therapy as directed\n15. Unable or unwilling to complete study visits or provide follow-up data as required per the study protocol\n16. Pregnant or lactating female","ALL","18 Years","85 Years",{"count":21,"type":22},35,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this single arm post-market observational study is to evaluate the short-term effectiveness of the Simeox 200 airway clearance device in improving airway clearance in adult patients aged 18 to 85 with bronchiectasis and chronic mucus hypersecretion. The study aims to establish a baseline for wet sputum weight production using the Simeox 200 device. Additionally, the study aims to assess the short-term effects of Simeox 200 on various outcomes, including lung function, respiratory symptoms, and health-related quality of life.\n\nThe study participants will undergo the following steps:\n\n1. Baseline Visit (V0): Participants will attend a baseline visit for eligibility screening, consent, a physical exam, and baseline assessments of various relevant parameters such as lung function, SpO2, and Patient-Reported-Outcomes.\n2. Treatment Sessions (V1): Participants will perform two supervised treatment sessions with the Simeox 200 device at the clinic, during which sputum will be collected and weighed.\n3. Home Use : Participants will use the device at home twice daily for 2 weeks, recording their usage and symptoms in a daily electronic diary.\n4. Final Clinic Visit (V2): Participants will return for a final clinic visit for repeat assessments.\n5. Follow-up Phone Call (14 days after V2): Participants will receive a follow-up phone call to assess ongoing symptoms and health status.",[28,29],"Bronchiectasis","Mucus; Plug",[28,31,32,33],"Mucus hypersecretion","Airway clearance technique","Bronchial drainage","NOT_YET_RECRUITING","2026-02-24",{"date":37,"type":38},"2026-03-02","ACTUAL",{"date":40,"type":22},"2026-02",{"date":42,"type":22},"2026-06",{"name":44,"class":45},"Inogen Inc.","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":66,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":46},"100620826","a-study-of-the-efficacy-and-safety-of-bronchoscopic-airway-clearance-and-amphotericin-b-spraying-in-patients-with-abpa-100620826","NCT07362667","A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA","A Prospective, Multicenter, Observational Cohort Study on the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With Allergic Bronchopulmonary Aspergillosis","Inclusion Criteria:\n\n1. Meet the diagnostic criteria of allergic bronchopulmonary aspergillosis, according to the ISHAM guidelines for the diagnosis and treatment of allergic bronchopulmonary aspergillosis (2024 revision), and the presence of mucus plugs or hyperattenuated mucus confirmed by chest high-resolution CT (HRCT).\n2. Active disease: Newly diagnosed allergic bronchopulmonary aspergillosis or an acute exacerbation after discontinuation of treatment (defined as a \\> 14 day history of clinical worsening or radiographic progression of allergic bronchopulmonary aspergillosis and a ≥50% increase in total serum IgE from the last recorded value during the stable phase, excluding other causes of the acute exacerbation) in patients with previously diagnosed allergic bronchopulmonary aspergillosis.\n3. Age ≥ 18 years old.\n\nExclusion Criteria:\n\n1. Allergic bronchopulmonary aspergillosis - serotype (i.e., meets the diagnostic criteria for allergic bronchopulmonary aspergillosis, but chest CT shows no obvious abnormality);\n2. Patients with absolute or relative contraindications to electronic bronchoscopy;\n3. Known history of allergy to amphotericin B or any of its excipients;\n4. Patients with bronchiectasis caused by human immunodeficiency virus infection, active tuberculosis, pulmonary malignant tumor or other non-allergic bronchopulmonary aspergillosis;\n5. Combined with other diseases requiring long-term systemic use of glucocorticoids or immunosuppressants (such as autoimmune diseases);\n6. Patients with previous or current smoking history;\n7. Pregnant or lactating women;\n8. Currently participating in other interventional clinical research;\n9. Any other conditions considered by the investigator to preclude participation in the study (e.g., nonadherence, predicted survival \\\u003C1 year, or severe mental illness that prevented cooperation).",{"count":55,"type":22},44,"OBSERVATIONAL","To evaluate the efficacy and safety of bronchoscopic airway clearance and amphotericin B spraying in the treatment of allergic bronchopulmonary aspergillosis",[59,60,61,62,63,64,65],"ABPA","Allergic Bronchopulmonary Aspergillosis","Allergic Bronchopulmonary Aspergillosis (ABPA)","Airway Clearance","Mucus Plug","Amphotericin B","Bronchoscope",[60,59,64,67,62,68],"bronchoscope","mucus plug","RECRUITING","2026-01-15",{"date":72,"type":38},"2026-01-23",{"date":74,"type":38},"2026-01-10",{"date":76,"type":22},"2028-12-31",{"name":78,"class":79},"Qianfoshan Hospital","OTHER",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":18,"enrollmentInfo":87,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":46},"100531568","prospective-multicentre-study-on-symptoms-in-first-onset-bronchial-asthma-in-children-and-adolescents-100531568","NCT06201494","Prospective Multicentre Study on Symptoms in First-onset Bronchial Asthma in Children and Adolescents","Inclusion Criteria:\n\n\\- Child 3 - 18 years old, first evaluation in pulmonary outpatient clinic for any of the following respiratory symptoms: cough, shortness of breath, chest tightness, wheezing, recurrent lower respiratory tract and lung infections, dyspnoea of any type, pathological listening findings.\n\nExclusion Criteria:\n\n* Other documented chronic respiratory, cardiovascular, neurological, genetic, infectious, metabolic disease, significant immaturity or other disease that may be accompanied by respiratory symptoms.","3 Years",{"count":88,"type":22},80,"Bronchial asthma may present with symptoms other than the commonly reported complaints (cough, chest tightness, shortness of breath and wheezing). Less common symptoms include chronic or recurrent productive cough, inspiratory dyspnoea or recurrent pneumonia. Children presenting with these symptoms are often diagnosed with asthma bronchiale and benefit from antiasthmatic management.",[91,92,93,94,95,96,97,98,99,100,29],"Asthma","Asthma in Children","Dyspnea","Cough","Pneumonia","Wheezing","Shortness of Breath","Chest Tightness","Lower Respiratory Tract and Lung Infections","Recurrent Respiratory Tract Infections","2024-06-14",{"date":103,"type":38},"2024-06-18",{"date":105,"type":38},"2023-01-01",{"date":107,"type":22},"2026-06-01",{"name":109,"class":79},"Charles University, Czech Republic"]